Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gecacitinib in Peri-transplant Period of HSCT in Myelofibrosis
NCT07471503Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2026
- Primary completion
- Apr 2029
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of jaktinib in myelofibrosis (MF), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07471503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07471503.